Future landscapes of women’s hormone-sensitive cancers: unraveling global trends, age stratification, and regional inequities (1990–2035) - Takeaways - MDSpire

Future landscapes of women’s hormone-sensitive cancers: unraveling global trends, age stratification, and regional inequities (1990–2035)

  • By

  • Yi Zhou

  • Min Jiang

  • Yutao Wu

  • Jiao Wang

  • Xiaoyu Li

  • Ke Shen

  • Tao He

  • Chi Zhang

  • Hui Zong

  • Rongrong Wu

  • Rajeev K. Singla

  • Qing Lv

  • Bairong Shen

  • May 1, 2026

  • 0 min

Share

  • 1

    Hormone-sensitive cancers (HSCs) are increasingly prevalent among women, particularly in the reproductive age group, with rising global incidence rates.

  • 2

    Breast cancer is the most common HSC subtype, with age-standardized incidence rates significantly higher in older women compared to younger women.

  • 3

    Lower socio-demographic index (SDI) countries experience faster-growing rates of HSCs, highlighting significant regional disparities in incidence and mortality.

  • 4

    Dietary risks, alcohol use, and tobacco are major contributors to breast cancer burden, with rising impacts of high fasting plasma glucose and BMI in certain regions.

  • 5

    Projected trends indicate that the global burden of HSCs will continue to rise through 2035, necessitating targeted prevention and intervention strategies.

Original Source(s)

Future landscapes of women’s hormone-sensitive cancers: unraveling global trends, age stratification, and regional inequities (1990–2035)

  • by Yi Zhou, Min Jiang, Yutao Wu, Jiao Wang, Xiaoyu Li, Ke Shen, Tao He, Chi Zhang, Hui Zong, Rongrong Wu, Rajeev K. Singla, Qing Lv, Bairong Shen

  • May 1, 2026

Related Content

Retraction: MicroRNA-935 directly targets FZD6 to inhibit the proliferation of human glioblastoma and correlate to glioma malignancy and prognosis

  • May 28, 2026

Glandular tissue–based versus anatomical landmark–based CTV delineation in postoperative breast cancer radiotherapy: a dosimetric comparison

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases